bioAffinity Technologies Regains Nasdaq Minimum Bid Price Compliance

What Happened

• bioAffinity Technologies, Inc. announced it has regained compliance with Nasdaq’s minimum $1.00 bid price requirement and the related rights/warrants rule. Nasdaq’s Staff had previously determined the company was out of compliance after its shares closed below $1.00 for 30 consecutive business days (June 16, 2026–July 29, 2026). The company appealed on August 6, 2026; a hearing was scheduled for September 8, 2026 but was cancelled after Nasdaq confirmed compliance on September 8, 2026. The company issued a press release on September 9, 2026 (Exhibit 99.1).

Key Details

• Nasdaq notice: bid price below $1.00 for 30 consecutive business days (June 16–July 29, 2026).
• Appeal filed: August 6, 2026; hearing scheduled and then cancelled on September 8, 2026 after Nasdaq confirmed compliance.
• Shares outstanding and market value: 1,166,625 shares outstanding; aggregate market value ≈ $10.4 million based on the September 8, 2026 closing price.
• Compliance context: company was initially ineligible for the usual 180-day cure period because it had completed a reverse stock split within the prior year.

Why It Matters

• Remaining listed on The Nasdaq Capital Market preserves trading liquidity and avoids the disruption and uncertainties of a delisting process.
• Investors should note the company met Nasdaq’s listing standards as of September 8, 2026, but should continue to monitor trading price and company disclosures for any future compliance developments.